Table 1 Summary of therapeutic antibodies combined with inhibition of autophagy
From: Targeting autophagy to overcome drug resistance: further developments
| Therapeutic antibodies | Targets | Combination therapy | Indications | References |
|---|---|---|---|---|
| Rituximab | CD20 | CQ | Non-Hodgkin lymphoma | [151] |
| Bevacizumab | VEGF | CQ | HCC | [152] |
| Cetuximab | EGFR | CQ | Vulvar squamous carcinoma | [147] |
| Overexpressed Bcl-2 | Colorectal adenocarcinoma | |||
| siRNA ATG7 | Lung adenocarcinoma | |||
| siRNA Beclin1 | ||||
| Gemtuzumab ozogamicin | CD33 | PP242 | Acute myeloid leukemia | [153] |
| AZD2014 | [154] | |||
| DN30 | Met | Baf | Cardiomyoblasts | [155] |
| DO24 | ||||
| Trastuzumab | HER2 | CQ | Breast cancer | [148] |
| Milatuzumab | CD74 | FTY720 | Mantle cell lymphoma | [156] |
| Tositumomab | CD20 | Overexpressed Bcl-2 | B cell malignancies | [157] |
| siRNA Beclin1 | ||||
| siRNA ATG 12 | ||||
| CH12 | EGFRvIII | siRNA ATG7 | HCC | [158] |
| siRNA Beclin1 | ||||
| β2M mAb | β2-microglobulin | Bortezomib | Multiple myeloma | [159] |
| PD-1 mAb | PD-1 | Pemetrexed + sildenafil | Non-small cell lung cancer | [160] |
| CTLA4 mAb | CTLA4 |
